Discontinued — last reported Q3 '25
DexCom Equity Method Investments increased by 0.7% to $219.50M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 89.6%, from $115.80M to $219.50M. Over 3 years (FY 2022 to FY 2025), Equity Method Investments shows an upward trend with a 125.5% CAGR.
An increase indicates strategic expansion through partnerships or joint ventures, while a decrease may signal divestments or impairment.
These are investments in entities where the company exercises significant influence but does not have full control. The...
Varies significantly based on corporate strategy; common in healthcare companies that partner with biotech startups or specialized diagnostic firms.
equity_method_investments| Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $19.00M | $35.00M | $38.50M | $38.50M | $39.80M | $43.60M | $46.30M | $119.30M | $115.80M | $115.80M | $216.90M | $218.00M | $219.50M |
| QoQ Change | — | +84.2% | +10.0% | +0.0% | +3.4% | +9.5% | +6.2% | +157.7% | -2.9% | +0.0% | +87.3% | +0.5% | +0.7% |
| YoY Change | — | — | — | +102.6% | — | +24.6% | +20.3% | +209.9% | +191.0% | +165.6% | +368.5% | +82.7% | +89.6% |